Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

Published:2010-06 Issue:3 Volume:11 Page:125-132
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Sierra-Madero Juan,Di Perri Giovanni,Wood Robin,Saag Michael,Frank Ian,Craig Charles,Burnside Robert,McCracken Jennifer,Pontani Dennis,Goodrich James,Heera Jayvant,Mayer Howard

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/hct1103-125

Reference12 articles.

1. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2. Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

3. Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®;Viruses;2024-03-27

2. iDVEIP: A computer‐aided approach for the prediction of viral entry inhibitory peptides;PROTEOMICS;2024-01-23

3. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds;International Journal of Molecular Sciences;2023-03-21

4. Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life;Pediatric Infectious Disease Journal;2022-08-09

5. HIV and liver disease;Aids Reviews;2022-06-28